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Abstract
Introduction: Measurement of prohormones representing different pathophysiological pathways could enhance risk 
stratification in patients with community-acquired pneumonia (CAP) and other lower respiratory tract infections (LRTI).
Methods: We assessed clinical parameters and five biomarkers, the precursor levels of adrenomedullin (ADM), 
endothelin-1 (ET1), atrial-natriuretic peptide (ANP), anti-diuretic hormone (copeptin), and procalcitonin in patients with 
LRTI and CAP enrolled in the multicenter ProHOSP study. We compared the prognostic accuracy of these biomarkers 
with the pneumonia severity index (PSI) and CURB65 (Confusion, Urea, Respiratory rate, Blood pressure, Age 65) score 
to predict serious complications defined as death, ICU admission and disease-specific complications using receiver 
operating curves (ROC) and reclassification methods.
Results: During the 30 days of follow-up, 134 serious complications occurred in 925 (14.5%) patients with CAP. Both PSI 
and CURB65 overestimated the observed mortality (X2 goodness of fit test: P = 0.003 and 0.01). ProADM or proET1 
alone had stronger discriminatory powers than the PSI or CURB65 score or any of either score components to predict 
serious complications. Adding proADM alone (or all five biomarkers jointly) to the PSI and CURB65 scores, significantly 
increased the area under the curve (AUC) for PSI from 0.69 to 0.75, and for CURB65 from 0.66 to 0.73 (P < 0.001, for both 
scores). Reclassification methods also established highly significant improvement (P < 0.001) for models with 
biomarkers if clinical covariates were more flexibly adjusted for. The developed prediction models with biomarkers 
extrapolated well if evaluated in 434 patients with non-CAP LRTIs.
Conclusions: Five biomarkers from distinct biologic pathways were strong and specific predictors for short-term 
adverse outcome and improved clinical risk scores in CAP and non-pneumonic LRTI. Intervention studies are warranted 
to show whether an improved risk prognostication with biomarkers translates into a better clinical management and 
superior allocation of health care resources.
 Trial Registration : NCT00350987.
Introduction
The assessment of disease severity and prediction of out-
come in lower respiratory tract infections (LRTI) and, in
particular, community-acquired pneumonia (CAP), is
essential for the appropriate allocation of health care
resources and for optimized treatment decisions. These
include hospital or intensive care unit admission, the
extent of diagnostic work-up, the choice and route of
antimicrobial agents and the evaluation for early dis-
charge. In an attempt to optimize and lower unnecessary
hospital admission rates, professional organizations have
developed prediction rules and propagated guidelines to
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stratify patients with CAP based on predicted risks for
mortality [1-3]. The pneumonia severity index (PSI) is a
well validated scoring system in North America based on
19 prognostic parameters [4]. The CURB65 score, a more
simplified assessment tool developed by the British Tho-
racic Society, focuses on only five predictors [5,6]. This
score is easier to calculate, but has a lower prognostic
accuracy. Both risk scores were validated for the predic-
tion of mortality only. Their ability to predict other
important adverse disease outcomes including the need
for ICU admission and complications due to the infection
has not been established. Patients with PSI risk classes 1,
2 and 3 should be considered as candidates for outpatient
treatment, but still a high percentage of subjects in these
risk classes may experience unexpected complications
indicating the need for improvement of these scores [7].
To improve the accuracy of clinical severity scores, pro-
hormones have been proposed as biomarkers that pro-
vide more detailed and complementary information [8-
25]. Several biomarkers have been related to disease
severity and outcome in LRTI and sepsis, including levels
of the cardiac hormone atrial-natriuretic peptide (ANP)
[13-17], the stress- and volume-dependent antidiuretic
hormone (ADH, vasopressin) [21-25], the endothelium
derived hormones endothelin-1 (ET-1) [11,18-20] and
adrenomedullin (ADM) [8-12], and procalcitonin (PCT)
a specific marker of bacterial infections [26-35].
The simultaneous measurement of a panel of prohor-
mones each reflecting a specific pathophysiological path-
way could enhance risk stratification in patients with
CAP and other LRTI. We therefore validated the useful-
ness of five previously reported prohormones for predict-
ing serious complications in patients with CAP and other
LRTI enrolled in the multicenter ProHOSP study [31,34].
Materials and methods
Study sample
We measured biomarker levels in all patients with LRTIs
enrolled in the multicenter ProHOSP study [31]. The
design of the ProHOSP study has been reported in detail
elsewhere [34]. In brief, from October 2006 to March
2008, a total of 1,359 consecutive patients with presumed
LRTIs from six different hospitals located in the northern
part of Switzerland were included. Patients were ran-
domly assigned to an intervention group, where guidance
of antibiotic therapy was based on PCT cut off ranges or
to a standard group where guidance of antibiotic therapy
was based on enforced guideline recommendations with-
out knowledge of PCT. The primary end-point in this
non-inferiority trial was a combined endpoint of adverse
medical outcomes within 30 days following the ED
admission. A further predefined secondary objective was
the evaluation of different biomarkers to predict serious
complications and all causes of mortality as compared to
established risk factors and clinical scores.
The study protocol was approved by all local ethical
committees, and written informed consent for the collec-
tion of blood on admission and during follow-up to mea-
sure biomarkers was obtained from all participants.
Definition of different LRTIs and severity assessment
We used web-based guidelines for a standardized care of
patients as defined previously [34]. Thereby, LRTI was
defined by the presence of at least one respiratory symp-
tom (cough, sputum production, dyspnea, tachypnea,
pleuritic pain) plus at least one finding during ausculta-
tion (rales, crepitation), or one sign of infection (core
body temperature >38.0°C, shivering, leukocyte count
>10 G/l or <4 G/l cells) independent of antibiotic pre-
treatment. CAP was defined as a new infiltrate on chest
radiograph [1,2,36,37]. Chronic obstructive pulmonary
disease (COPD) was defined by post-bronchodilator
spirometric criteria according to the Global initiative for
chronic Obstructive Lung Disease (GOLD)-guidelines as
a FEV1/FVC ratio below 70% [36,38]. Acute bronchitis
was defined as LRTI in the absence of an underlying lung
disease or focal chest signs and infiltrates on chest x-ray,
respectively [37]. The Pneumonia Severity Index (PSI)
and the CURB65 scores were calculated in all patients as
described on admission to the emergency department
[4,6]. Our web-based guidelines provided published crite-
ria for ICU admission based on the 2001 American Tho-
racic Society (ATS) criteria [1]. In brief, ICU admission
s h o u l d  b e  c o n s i d e r e d  i n  p a t i e n t s  w i t h  s e v e r e  C A P ,
defined as the presence of either one of two major criteria
(need for mechanical ventilation, septic shock), the pres-
ence of two of three minor criteria (systolic blood pres-
sure <90 mmHg, multilobar disease, PaO2/FIO2ratio
<250) or more than two CURB points. For COPD
patients, ICU criteria included severe acidosis or respira-
tory failure (pO2 <6.7 kPa, pCO2 >9.3 kPa, pH <7.3), no
response to initial treatment in the emergency depart-
ment or worsening mental status (confusion, coma)
despite adequate therapy.
Analysis population, endpoints and covariates
The primary analysis population contains all 925 patients
with the final diagnosis of CAP. In a second step, perfor-
mance of developed models was extrapolated to patients
with non-CAP LRTI (that is, acute bronchitis and exacer-
bation of COPD).
The primary endpoint of this prognostic study was seri-
ous complications defined as death from any cause, ICU
admission, or disease specific complications defined as
local or systemic complications from LRTI including per-
sistence or development of pneumonia (including noso-
comial), lung abscess, empyema or acute respiratorySchuetz et al. Critical Care 2010, 14:R106
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distress syndrome within 30 days following inclusion.
The secondary endpoint was overall survival within 30
days following study inclusion. Outcomes were assessed
during hospital stay at days 3, 5, 7, at hospital discharge,
and by structured phone interviews after 30 days by
blinded medical students and adjudicated by an indepen-
dent data-monitoring committee [31,34].
Pre-defined covariates for the prognostic models were
the covariates included in the CURB65 score (all covari-
ates except for confusion as continuous variables) and the
five prohormones. Prohormone levels and urea were log-
transformed prior to all analyses to normalize their distri-
bution. In exploratory analysis we also explored all cova-
riates included in the PSI score.
Biomarker selection and measurement
We selected five prohormones because of reported asso-
ciations with death or serious complications, biologic
plausibility and availability [8-25]. We measured PCT and
proADM as markers of bacterial infection and inflamma-
tion; the atrial-natriuretic peptide proANP and proET-1
as markers of cardiac and endothelial function, and the
vasopressin precursor copeptin as a marker of stress and
fluid balance. ProADM, proET-1, proANP and copeptin
were batch-measured in plasma with new sandwich
immunoassay as described elsewhere [8,25,39-41]. The
assays have analytical detection limits of 0.08 nmol/L, 0.4
pmol/L, 4.3 pmol/L and 0.4 pmol/L, respectively. PCT
was measured with a high sensitive time-resolved ampli-
fied cryptate emission (TRACE) technology assay (PCT
Kryptor®, B.R.A.H.M.S. AG, Hennigsdorf, Germany). The
assay has a detection limit of 0.02 μg/L and functional
assay sensitivity of 0.06 μg/L.
Statistical analysis
Development and assessment of prognostic models
To assess the univariate predictive potential of the five
biomarkers and all covariates included in the PSI and
CURB65 scores on the endpoints we first calculated the
areas under the ROC curve (AUCs) for each covariate
separately. The univariate association between the two
most predictive biomarkers, proADM and proET1,
respectively, and the risk of a serious complication and
death, respectively, was also estimated using a general-
ized additive model. In addition, we assessed the calibra-
tion of the PSI and CURB65 scores using X2 goodness of
fit tests. Expected risks for these scores were based on the
risks reported in the original PSI and CURB65 publica-
tions [4,6]. In both cases, we used observed risks from all
patients (derivation and validation cohorts) from those
studies.
Second, we assessed the significance and improvement
in AUCs if biomarkers were included into a logistic model
in addition to either the CURB65 or the PSI risk score.
Third, we fitted the three predefined multivariable logis-
tic regression models for the two separate endpoints, that
is, serious complications and death. The models con-
tained the CURB65 covariates alone, jointly with
proADM, and jointly with all remaining biomarkers.
Analyses for both endpoints address the limitation that
the CURB65 and PSI scores were originally designed to
assess mortality risks as the main outcome. In order to
avoid over-fitting in view of the limited number of
patients reaching the endpoints we restricted this analysis
to covariates from the CURB65 score. Further, we chose
to look at proADM separately because it had the best
track record based on earlier publications [8-12]. In addi-
tion, we assessed how well the multivariable models,
which were developed for CAP patients only, extrapolate
to patients without CAP.
The performance of the prognostic models was
assessed by ROC curves, the AUC and the mean Brier
score. The Brier score for the ith individual is the squared
difference between his predicted probability of an event
and the outcome (0 = no event, 1 = event). The mean
Brier score is the average Brier score amongst all patients.
For an individual, the Brier score can range from 0 (con-
cordant prediction and outcome) and 1 (discordant pre-
diction and outcome); a prediction of 50% has a score of
0.25 both when the outcome is 0 or 1 [42].
The development and assessment of prognostic models
based on the same dataset may lead to over-fitting and
thus over-optimistic conclusions. To avoid this bias we
used for all performance measures optimism-corrected
bootstrap validation with 1,000 bootstrap replications
[42,43]. Because the study recruited patients from six dif-
ferent hospitals, we additionally performed six-fold
cross-validation and fitted the model based on data from
five hospitals, to evaluate performance on patients from
the remaining hospital. The average performance mea-
sure over all six left-out hospitals provides a conservative
estimate of average performance on a similar hospital to
those included in the study. ROC curves were optimism-
corrected or cross-validated by vertical averaging, that is,
by averaging over true positive rates at fixed false positive
rates. For comparing the model with all CURB65 covari-
ates vs. the model with CURB65 covariates and all five
biomarkers, we also assessed reclassification by reclassifi-
cation tables (for risk cut-offs at 5%, 10%, and 20%), net
reclassification improvement and integrated discrimina-
tion improvement [44]. These measures were either
based on predictions from a model fit on the full dataset
or, as a sensitivity analysis, on out-of-sample predictions
from leave-one-hospital-out cross-validation as
described above. In both cases, we used the average pre-
dicted risks over all imputed datasets (see below).
Finally, we assessed the additional prognostic value of
prohormones on Days 3, 5, and 7 of follow-up, respec-Schuetz et al. Critical Care 2010, 14:R106
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tively, by modeling the time to the first serious complica-
tion as depending on the initial prohormone value as well
as the time-updated biomarker value using the Cox pro-
portional hazards regression models with time-depen-
dent covariates.
Treatment of missing values
We used multiple imputations by chained equations to
deal with missing covariate and biomarker values. The
imputation dataset consisted of all 1,359 ProHOSP
patients (that is, including CAP and non-CAP LRTI) and
the following variables: All covariates included in the der-
ivation of the PSI or CURB65 risk scores, biomarkers val-
ues on Days 0, 3, 5, and 7, randomization arm, final
diagnosis, total antibiotics exposure, length of hospital
stay as well as death, ICU admission, complication, or
disease recurrence within 30 days of randomization. Out-
comes were also included in the imputation to avoid bias.
All reported results were aggregated over five imputed
datasets except for the time-dependent Cox regression,
which was based on the first imputed dataset only.
Statistical software
All analyses were performed with R 2.5.1 (R Foundation
for Statistical Computing, Vienna, Austria). We used the
contributed R packages mice for imputation of missing
values, and ROCR for ROC analysis [45-47].
Results
Patient population
A total of 1,359 persons with the presumed diagnosis of
LRTI were included. A majority of patients (92.5%) were
admitted to the hospital with a median length of stay of
eight (interquartile range (IQR) 4 to 12) days. CAP was
diagnosed in 925 patients, which is the primary popula-
tion studied in this analysis. Exacerbation of COPD was
diagnosed in 228, acute bronchitis in 151, and 55 patients
had another final diagnosis than LRTI. During the 30
days of follow-up, 170 patients (12.5%) with LRTI had at
least one serious complication including death in 67
patients (4.9%), need for ICU admission in 103 patients
(7.6%) and development of empyema in 31 patients
(2.3%). Most serious complications occurred in the 925
patients with CAP (n = 134, 14.5%). In CAP patients,
death occurred in 50 patients (5.4%), need for ICU admis-
sion in 83 patients (8.9%) and disease-specific complica-
tions, which consisted of empyema only, in 31 patients
(3.4%). Of note, some patients experienced more than
one serious complication. The number of patients with
CAP in the six participating centers ranged between 122
and 210 with between 19 and 28 serious complications
per center. Baseline characteristics and median levels of
the biomarkers in primary analysis population (CAP
patients) are presented in Table 1. Biomarkers were all
positively inter-correlated with rank correlations ranging
from 0.23 (between PCT and ProANP) to 0.87 (between
proET1 and proADM).
All biomarkers on admission were available in 94.8% of
patients. The most frequently missing covariate con-
tained in the CURB65 score was urea which was missing
in 19.1% of patients, primarily because it was only rarely
measured in one participating hospital. The number of
patients with a complete assessment of CURB65 covari-
ates and biomarkers at baseline was 539 (58%). In patients
who were alive and remained in hospital until the respec-
tive follow-up day, all biomarker values on Days 3, 5, and
7 of follow-up were available in 91.1%, 87.6% and 86.1% of
patients, respectively.
Calibration of PSI score and CURB65 score
Both PSI and CURB65 significantly overestimated the
mortality risk in CAP patients (P = 0.003 and 0.01 for X2
goodness of fit test). This overestimation occurred in
almost all risk categories (Table 2) and also in all hospi-
tals. Only one death was observed in 423 patients with
PSI Classes 1 to 3. In contrast, patients in PSI Class 1 had
already a 4.8% incidence of serious complications.
Univariate discriminatory power of biomarkers
Discriminatory power of biomarkers for predicting seri-
ous complications in CAP patients as assessed by the area
under the ROC curve (AUC) ranged from 0.66 for
proANP to 0.72 for proADM and proET1 (Table 1). Of
note, the best biomarkers had higher AUCs than the
CURB65 (AUC = 0.66) or the PSI score (AUC = 0.69) as
well as all individual covariates included in these scores.
Discriminatory power of biomarkers for predicting
death ranged between 0.60 for PCT to 0.76 for proADM
and 0.79 for proANP. CURB65 and PSI score had AUCs
of 0.74 and 0.84, respectively. Again, the best biomarker
h a d  a  h i g h e r  A U C  t h a n  a l l  c o v a r i a t e s  i n c l u d e d  i n  t h e
CURB65 or PSI scores (data not shown).
Corresponding ROC curves are displayed in Figure 1
(all biomarkers, PSI and CURB65). Figure 2 displays the
estimated association of the prohormones proADM and
proET1 with the risk of serious complications and death,
respectively.
Discriminatory power of biomarkers adjusted for risk 
scores
A combination of proADM in a logistic regression model
with either the CURB65 or the PSI risk score for the pre-
diction of serious complications yielded significant
effects for proADM (both P < 0.001); the odds ratio by
one standard deviation increase of log-proADM was 2.11
(95% CI 1.69 to 2.64) and 1.98 (95% 1.59 to 2.47) for the
two models, respectively. Likewise, the AUC (as assessed
by six-fold cross-validation) increased from 0.66 to 0.73
and from 0.69 to 0.75, respectively. Adding all biomarkersSchuetz et al. Critical Care 2010, 14:R106
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instead of proADM alone did not lead to a further
improvement of the models (P = 0.19 and 0.15, respec-
tively). Results were similar for a complete-case analysis
which did not impute any missing data (P < 0.001 for
proADM combined with CURB65 and P  = 0.004 for
proADM combined with the PSI score).
For predicting mortality in CAP patients, the addition
of proADM to CURB65 or PSI, respectively, was again
significant (both P < 0.001) with odds ratios of 2.08 (95%
CI 1.52 to 2.85) by one standard deviation increase of log-
proADM and 1.76 (95% CI 1.27 to 2.42), respectively. The
AUC increased from 0.74 to 0.80 and from 0.84 to 0.86,
respectively. Adding all biomarkers instead of proADM
alone lead to a further improvement of the model for
CURB65 (P = 0.03) but not for the PSI (P = 0.38).
Multivariable statistical models
The multivariable logistic model for the primary and sec-
ondary endpoint in CAP patients with all CURB65 cova-
riates and proADM is displayed in Table 3. Note that for
the primary endpoint older patients are less likely to
experience serious complications after adjustment for
other covariates.
ROC curves for all pre-defined multivariable models
for the prediction of serious complications and mortality
in CAP patients and corresponding performance mea-
Table 1: Characteristics of CAP patients at admission (n = 925)
Characteristics All CAP patients
(n = 925)
Serious complications (n = 134) No serious complications
(n = 791)
P AUC
Demographic characteristics
-Age (years)* 72 (59 to 82) 74 (62 to 82) 72 (58 to 82) 0.33 0.53
- Sex (male) - no. (%) 544 (58.8) 87 (64.9) 457 (57.8) 0.12
Coexisting illnesses - no. (%)
-Coronary heart disease 183 (19.8) 38(28.4) 145 (18.3) 0.007 -
-Renal dysfunction 206 (22.3) 58 (43.3) 148 (18.7) <0.001 -
-COPD 282 (30.5) 58 (43.3) 224(28.3) 0.001 -
Clinical findings
-Confusion - no. (%) 87 (9.4) 19 (14.2) 68 (8.6) 0.04 -
-Respiratory rate (breaths/minute)* 20 (16 to 25) 24 (18 to 30) 20 (16 to 25) <0.001 0.63
-Systolic blood pressure (mmHg)* 132 (119 to 148) 120 (105 to 140) 134 (120 to 150) <0.001 0.62
-Heart rate (beats/minute)* 95 (82 to 108) 99 (81 to 114) 94/102 to 106) 0.02 0.56
-Body temperature (C°)* 38.1 (37.2 to 38.9) 38.0 (37.1 to 38.7) 38.1 (37.3 to 38.9) 0.19 0.53
Biomarkers
-Procalcitonin (μg/l)* 0.71 (0.44 to 1.53) 1.12 (0.66 to 2.39) 0.66 (0.43 to 1.41) <0.001 0.66
-ProADM (nmol/l)* 1.1 (0.9 to 1.3) 1.4 (1.1 to 1.8) 1.1 (0.9 to 1.3) <0.001 0.72
-ProANP (pmol/l)* 9.1 (7.1 to 12.1) 11.2 (8.2 to 14.4) 8.7 (6.7 to 11.7) <0.001 0.65
-ProET1 (pmol/l)* 7.8 (6.7 to 9.3) 9.6 (7.6 to 11.3) 7.6 (6.6 to 8.9) <0.001 0.72
-Copeptin (pmol/l)* 4.0 (3.0 to 5.5) 5.4 (4.0 to 8.2) 3.8 (2.9 to 5.2) <0.001 0.70
Risk assessment at admission
-PSI points* 94 (67 to 116) 116 (95 to 141) 91/67 to 116) <0.001 0.69
-PSI class* 4 (2 to 4) 4 (4 to 5) 4 (2 to 4) <0.001 0.67
-CURB-65 points* 2 (1 to 2) 2 (1 to 3) 2 (1 to 2) <0.001 0.66
Baseline characteristics based on first imputed dataset. P-values according to Wilcoxon rank sum test or chi-square test, respectively. AUCs 
correspond to averaged results over all imputed datasets and were calculated for continuous characteristics only.
CAP, community-acquired pneumonia; PSI, pneumonia severity index; CURB65, confusion, uremia, respiratory rate, blood pressure, age 65 years 
or greater; AUC, area under the ROC curve; *expressed as median (interquartile range, IQR).Schuetz et al. Critical Care 2010, 14:R106
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sures are displayed in Table 4 and Figure 3. All multivari-
able models improved the prediction of serious
complications as compared to the PSI score and CURB
covariates. However, the differences between the three
multivariable models according to the AUC and the Brier
score appeared to be small. Cross-validated AUC's for the
model based on CURB65 covariates and proADM ranged
between 0.72 to 0.81 for the respective hospital that was
left-out from the model fitting. The cross-validated AUC
of 0.73 and Brier score of 0.14 for the center which had
urea missing for almost all patients tended to be poorer
than for other hospitals.
A reclassification [44] table of the model with CURB65
covariates only vs. the model with CURB65 covariates
and biomarkers is shown in Table 5. Reclassification
methods showed significant benefit from adding bio-
markers to clinical covariates. Specifically, net reclassifi-
cation improvement and integrated discrimination
improvement were 0.17 (P < 0.001) and 0.04 (P < 0.001),
respectively, if based on predictions derived on the full
dataset, and 0.13 (P = 0.01) and 0.04 (P < 0.001), if based
on out-of-sample predictions from leave-one-hospital out
cross-validation.
Prognostic value of biomarker values measured during 
follow-up
Boxplots of measured ProADM levels on admission and
during follow-up in patients with and without serious
complications are displayed in Figure 4. Sixty-eight per-
cent (91/134) of first serious complications, particularly
ICU admission, occurred within two days of randomiza-
tion, that is, prior to the first scheduled follow-up visit on
day 3.
The hazards for the time to the first serious complica-
tion depending on the initial ProADM level or the time-
updated ProADM level, were increased by 2.23 (95% CI
1.91 to 2.61) and 2.44 (95% CI 2.08 to 2.85) per two-fold
increase in ProADM. When both the initial and the time-
updated value of ProADM were included in the model,
initial ProADM did not remain a significant predictor (P
= 0.49), whereas the time-updated value remained signif-
icant (P < 0.001) suggesting that the latter is a better pre-
dictor for future serious complications. The same was
found when the Cox regression was additionally adjusted
for the CURB65 covariates.
Findings for other biomarkers were consistent. For all
biomarkers, the time-updated value was a stronger pre-
dictor than the initial value though for PCT and copeptin
also the initial value of the marker remained significant in
the model with both the initial and the time-updated
marker (P = 0.046 and P = 0.03, respectively).
Performance of multivariable statistical models in LRTI 
patients without CAP
The multivariable models for predicting serious compli-
cations developed in CAP patients extrapolated well if
evaluated in 434 patients with presumed other LRTI in
the ProHOSP trial. The AUCs for these patients and the
Table 2: Predicted and observed number of events according to PSI and CURB65 risk category in CAP patients (n = 925)
P S I  c l a s s 1 2345
Predicted death risk (%)* 0.18% 0.63% 2.74% 8.31% 29.62%
Observed data
- n 104 139 180 351 151
- Number of deaths 0 (0.0%) 0 (0.0%) 1 (0.6%) 23 (6.6%) 26 (17.2%)
- Number of ICU or death 4 (3.8%) 7 (5.0%) 8 (4.4%) 55 (15.7%) 44 (29.1%)
- Number of serious complications 5(4.8%) 12 (8.6%) 13 (7.2%) 60 (17.1%) 44 (29.1%)
CURB65 score 0 123 4  o r  5
Predicted death risk (%)* 0.58% 1.66% 9.02% 16.11% 35.10%
Observed data
- n 194 233 296 167 35
- Number of deaths 0 (0.0%) 4 (1.7%) 25 (8.4%) 10 (6.0%) 11 (31.4%)
- Number of ICU or death 6 (3.1%) 19 (8.2%) 44 (14.9%) 31 (18.6%) 18 (51.4%)
- Number of serious complications 7 (3.6%) 30 (12.9%) 46(15.6%) 33(19.8%) 18(51.4%)
* Based on risks reported in the original PSI and CURB65 publications (derivation and validation cohorts) [4,6].Schuetz et al. Critical Care 2010, 14:R106
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model with all CURB65 covariates and proADM, or with
all biomarkers, respectively, were both 0.80 and thus bet-
ter than on the original population. There was also no
indication of serious miscalibration of these models: A
total of 36 serious complications were observed in non-
CAP patients compared to predicted numbers of compli-
cations of 41.2 and 40.2 patients according to the two
models, respectively (P = 0.39 and P = 0.48 for X2 good-
Figure 1 Univariate association of the biomarkers with serious complications (left panel) and death (right panel). ProADM (black, solid line), 
proET1 (black, dashed line), PSI class (grey, dashed line) and CURB65 score (grey, dash-dotted line).
Figure 2 Estimated association of proADM and proET1 levels with risk of serious complications (upper black line) and death (lower blue 
line). Estimates are based on generalized additive models and shaded gray regions correspond to (point-wise) 95% confidence intervals. The rugs at 
the bottom of the plots display the distribution of the biomarker.Schuetz et al. Critical Care 2010, 14:R106
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ness of fit test). The model with only clinical covariates
extrapolated worse with an AUC of 0.75 in non-CAP
patients and some evidence of miscalibration with 49.7
predicted events (P = 0.04).
Discussion
In this large community-based sample of patients with
CAP and other LRTI from a multicenter study [34], five
prohormones from distinct biologic pathways were spe-
cific predictors for short term serious complications with
moderate improvement of clinical risk scores. Thereby,
this study validates a series of previous smaller trials
demonstrating a clinical utility of prohormones for an
optimized risk prediction in LRTI [8-25].
Meaningful statistical assessment of the potential clini-
cal utility of a biomarker is challenging. In addition to
classical performance measures like two group compari-
sons and ROC curves, more clinically meaningful statisti-
cal approaches have been put forward [44,48]. We
performed several different statistical analyses to investi-
gate the added value of biomarkers to clinical scores;
more specifically, we assessed the addition of prohor-
mones to PSI and CURB65 scores per se and to a multi-
variate regression model based on CURB65 covariates.
We measured the prognostic performance of these mod-
els by several different quantities (AUC, Brier score and
reclassification methods). Thereby, some prohormones,
namely proADM, improved both clinical risk scores and
were superior per se for serious complications prediction.
The incorporation of a combination of biomarkers
reflecting systemic inflammation, endothelial dysfunc-
tion, stress and cardiac function to the clinical risk scores
improved their prognostic accuracy for prediction of
short term complication rate and to a lesser extent mor-
tality. When comparing the biomarkers to models based
on raw clinical predictors included in the CURB65 score,
the improvement was less extensive as shown by a rela-
tively small increase in the AUC, but reclassification
methods still established highly significant improvements
of the model due to addition of the prohormones. Thus,
as demonstrated previously for biomarkers in cardiovas-
cular disease [44], prohormones significantly improve
classification of patients into pre-defined risk groups.
The combination of clinical predictors and prognostic
biomarkers has been suggested as a promising approach
to optimize the prognostic certainty and thus the man-
agement of LRTI patients [49]. The information on the
disease driven host-response mirrored in the circulating
level of a biomarker may provide insights into the
pathophysiology and prognosis of a disease process. As a
quantifiable tool it facilitates risk stratification and moni-
toring of therapy as a surrogate outcome measure. In the
future, a panel of biomarkers might help in delineating
distinct populations of patients with discrete pathologies
- a prerequisite to enable the targeted application of spe-
cific biologically rational therapies. In this trial, we vali-
date the prognostic performance of five promising,
rapidly measurable prohormones [8-25]. ADM is one of
the most potent vasodilating agents with immune modu-
lating, metabolic and bactericidal properties [40,50].
Table 3: Logistic model for the prediction of serious complications or death using proADM and all CURB covariates
Serious complications Death
OR 95% CI P OR 95% CI P
Intercept 0.08 (0.06, 0.11) <0.001 0.02 (0.01, 0.03) <0.001
Confusion - yes 2.05 (1.07, 3.91) 0.03 2.30 (1.01, 5.22) 0.047
Urea
(by two-fold increase)
1.59 (1.05, 2.41) 0.03 1.51 (0.85, 2.70) 0.16
Respiratory rate
(by +10 breaths/minute)
1.38 (1.10, 1.74) 0.01 1.23 (0.88,1.72) 0.23
Systolic blood pressure
(by +10 mmHg)
0.90 (0.82, 0.98) 0.02 0.90 (0.79, 1.03) 0.11
Age
(by +10 years)
0.82 (0.71, 0.95) 0.01 1.62 (1.18, 2.23) 0.003
ProADM*
(by 2-fold increase)
1.92 (1.44, 2.57) <0.001 1.84 (1.18, 2.87) 0.01
OR, Odds ratio, CI, Confidence interval.
Intercept corresponds to a person without confusion, urea of 7 mmol/l, respiratory rate of 20 breaths/minute, systolic blood pressure of 130 
mmHg, age 70 years and ProADM of 1 nmol/l.
* OR (95% CI, P-value) for proADM in the complete case analysis without imputation of missing data are 1.61 (1.13 to 2.31; P = 0.01) for the 
prediction of serious complications and 1.65 (0.97 to 2.79; P = 0.06) for the prediction of death.Schuetz et al. Critical Care 2010, 14:R106
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Atrial-natriuretic peptide, a member of the family of
natriuretic peptides regulates a variety of physiological
parameters [51]. In septic states, ANP levels may mirror
both, the inflammatory cytokine response correlated
with the severity of infection, as well as the presence of
disease-relevant comorbidities, namely heart failure and
renal dysfunction [41,52]. Copeptin, stoichiometrically
cleaved from the vasopressin precursor, has hemody-
namic and osmoregulatory effects, and mirrors the indi-
vidual stress response [53]. Endothelin-1 is an important
vasoconstrictor and correlates with disease severity and
short term outcome [11,18-20]. Unfortunately, these
mature hormones are difficult to measure with high reli-
ability because they are not stable at room temperature
and have a rapid clearance from the circulation limiting
their use in clinical routine. For this reason new sandwich
immunoassays have been recently introduced that mea-
sure the more stable precursor fragments (proANP,
Copeptin (proADH), proET-1 and proADM) [8,25,39-
41]. Unlike the mature peptides, these precursors can be
detected for hours in the circulation. Because of the stoi-
chiometric generation, these prohormones correlate with
the release of the active peptides, a condition similar to
that of insulin and C-peptide. Thus, these precursor pep-
tides can be used to indirectly measure the release of the
mature hormone under physiological and pathological
conditions.
We focused our analysis on initial risk assessment and
initial prohormone levels, but also explored the utility of
repeated biomarker measurements. We used Cox pro-
portional hazards regression models with time-depen-
dent covariates (in addition to the baseline biomarker)
and found that this model significantly improves upon
the model with baseline covariates only. Moreover, we
found that the baseline value of the biomarker is no lon-
ger significant after adjustment for the current biomarker
value suggesting that the absolute value of the current
biomarker value contains most information regarding
Table 4: Performance of multivariable models for the prediction of death, ICU or complication in CAP patients (n = 925)
Endpoint Model Bootstrap-corrected 
accuracy measure
Leave-one-hospital-out cross-validation
Accuracy calculated on left out hospital
Mean Range
Serious complication* CURB covariates
-AUC 0.75 0.75 0.67 to 0.83
-Brier score 0.11 0.11 0.09 to 0.15
CURB covariates + proADM
-AUC 0.76 0.76 0.72 to 0.81
-Brier score 0.10 0.11 0.09 to 0.14
CURB covariates + all biomarkers
-AUC 0.76 0.76 0.71 to 0.81
-Brier score 0.11 0.11 0.09 to 0.14
Death CURB covariates
-AUC 0.80 0.81 0.72 to 0.87
-Brier score 0.05 0.05 0.03 to 0.07
CURB covariates + proADM
-AUC 0.81 0.82 0.71 to 0.87
-Brier score 0.05 0.05 0.03 to 0.07
CURB covariates + all biomarkers
-AUC 0.80 0.81 0.72 to 0.88
-Brier score 0.05 0.05 0.03 to 0.07Schuetz et al. Critical Care 2010, 14:R106
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future prognosis and the baseline value (as well as the
change in the biomarker from baseline to follow-up) are
less relevant. Further research is needed to derive clinical
decision rules based on time-updated biomarker values.
The development of sepsis from a localized infection is
a dynamic continuum and in the majority a sequelae of
CAP [54]. The severity of a disease determines the con-
sumption of costly and limited health-care resources. An
early and adequate diagnosis and risk assessment is, thus,
pivotal for optimized risk-adapted care of patients with
severe infections. Scoring systems, such as the PSI, are
well validated prognostic tools to determine mortality
risks and rely mostly on age as the main driver of mortal-
ity [4]. However, calculation of the PSI in daily practice is
time consuming which limits its dissemination and
implementation in routine care [55]. In addition, the PSI
is not a validated predictor for the clinically relevant rate
of serious complications. Other clinical prediction rules
have focused to predict eligibility for ICU admission.
Multiple ICU prediction rules have been proposed
including the Infectious Disease Society of America/
American Thoracic Society (IDSA/ATS) criteria, the
SMART-COP and scores based on the PIRO (Predisposi-
tion, insult/infection, response, and organ dysfunction)
concept [56-60].
We focused our analysis on a combined endpoint of
serious complications, which included mortality, ICU
admission and disease-specific complications. The
strength of this approach is the clinical relevance for ini-
tial site-of-care decisions as patients experiencing one of
these serious complications should arguably not be man-
aged in the outpatient setting. However, heterogeneity of
this combined endpoint makes prognostication more
challenging as shown by the lower AUCs in ROC curves
in this study when compared to mortality prediction
alone. While age and comorbidities are major drivers of
mortality, extent and severity of infection and organ fail-
ure may be the most important predictors for ICU admis-
sion. In this regard, combination of clinical parameters
and biomarkers seems a promising approach.
A s  a  l i m i t a t i o n  o f  t h i s  s t u d y ,  o u r  f i n d i n g s  m a y  n o t
unconditionally be applied to a general LRTI population
because of selection bias in regard to exclusion criteria of
the underlying randomized controlled trial. Since the
PCT-guided group in the ProHOSP trial was non-inferior
to the guidelines group with respect to the risk of adverse
outcomes, treatment assignment was not considered any
further in this analysis. Switzerland has previously been
shown to have very low rates of ICU-acquired nosoco-
mial infections and related mortality; thus country-spe-
cific differences may limit generalizability and external
Figure 3 ROC curves of multivariable models for the prediction of serious complications (left panel) and death (right panel) during 30 days 
of follow-up. Models are based on CURB65 covariates alone (grey, dash-dotted lines), or jointly with proADM (black, solid lines) or all five biomarkers 
(black, dashed lines), respectively, ROC curve estimated by six-fold cross-validation (leave-one-hospital out). The predictive accuracy of the PSI class 
(gray, dashed lines) is added as a comparison.Schuetz et al. Critical Care 2010, 14:R106
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validation is warranted [61]. Further, covariates for risk
score determination (but not biomarker values) were rel-
atively frequently missing in our dataset. We used multi-
ple imputations to deal with missing variables, but this
methodology may not be correct on an individual patient
basis and may explain some of the PSI and CURB65 mis-
calibration observed within this study. Although we pro-
vided web-based guidelines based on ATS criteria for
ICU admission of patients, the final decision for ICU
admission was left to the treating physician team. Other
clinical risk scores have been suggested for prediction of
ICU admission [56-60]. However, as not all covariates
were prospectively collected we did not compare bio-
markers with these scores.
Previous studies have demonstrated the clinical and
scientific impact of the biomarker PCT on the antibiotic
management of LRTI [26-32] but up to now, no study has
investigated the clinical utility of a prognostic biomarker
on the management of patients with LRTI. Because of its
high prevalence and associated large need of health care
resources, accurate prognostication and improved site-
of-care decisions have high relevance for public health,
both for primary and hospital care. The ultimate clinical
utility of a biomarker is defined by the degree it improves
clinical decision making and adds timely information
beyond that of readily available information from clinical
examination. Observational studies alone cannot provide
such information, but may help to provide a rationale for
future intervention studies. These are now warranted to
show whether biomarker measurement improves risk
prognostication and thus the clinical management of
patients with LRTI.
Conclusions
Our data suggest that the addition of a panel of prohor-
mones of distinct biological pathways, particularly
proADM, to established CAP risk scores improves the
risk stratification for serious complications and mortality
in CAP patients. If these results are validated, the incor-
poration of one or several biomarkers in clinical practice
for the prediction of adverse prognosis could help to opti-
mize admission decisions in patients with LRTI and CAP
upon hospital admission and in the emergency depart-
ment.
Key messages
• The simultaneous measurement of different prohor-
mones each reflecting distinct pathophysiological
Table 5: Reclassification table for serious complications in clinical covariates only model compared to clinical covariates 
plus all biomarkers model
Model with clinical covariates and all biomarkers
Model with clinical covariates only Risk categories ≤5% >5 to 10% >10 to 20% >20% Row total
≤5%
Number 116 22 3 0 141
Actual risk 0.04 0.00 0.33 - 0.04
>5 to 10%
Number 96 160 46 2 304
Actual risk 0.03 0.04 0.09 0.5 0.05
>10 to 20%
Number 39 6 1 5 43 4 287
Actual risk 0.33 0.08 0.18 0.32 0.16
>20%
Number 0 1 32 160 193
Actual risk - 0.00 0.09 0.39 0.34
Column total
Number 215 279 235 196
Actual risk 0.04 0.05 0.15 0.38Schuetz et al. Critical Care 2010, 14:R106
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pathways could enhance risk stratification in patients
with CAP.
• The precursor levels of adrenomedullin (ADM),
endothelin-1 (ET1), atrial-natriuretic peptide (ANP),
anti-diuretic hormone (copeptin), and procalcitonin
(PCT) on admission and during follow up, showed all
high prognostic accuracies for mortality and serious
complications.
• For the prediction of serious complications,
ProADM and proET1 alone had stronger discrimina-
tory power than the PSI or CURB65 score or any
components of these risk scores. The inclusion of
proADM alone (or all five biomarkers jointly) in addi-
tion to the PSI or CURB65 scores, respectively, signif-
icantly improved the AUC for prediction of serious
complications.
• Reclassification methods also established highly sig-
nificant improvement for models with biomarkers
compared to models based on clinical covariates only.
• Future intervention studies are warranted to show
whether an improved risk prognostication with bio-
markers translates into a better clinical management
and superior allocation of health care resources.
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